Arcadia Biosciences (RKDA)

Data from SEC filings
Employee count
Shareholder alignment
Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
On June 2, 2021, Arcadia Biosciences, Inc. (the “Company”) held its 2021 annual meeting of stockholders (“Annual Meeting”). The Annual Meeting was adjourned until June 15, 2021 and then until June 30, 2021 to allow additional time to obtain a quorum for the Annual Meeting.
On June 30, 2021, the Company reconvened its adjourned Annual Meeting. Stockholders holding and entitled to vote 10,840,822 shares of common stock of the Company, or approximately 50.80% of the total outstanding shares of common stock on the record date for the Annual Meeting, were present at the Annual Meeting either by attendance via live audio webcast or by proxy. At the Annual Meeting, the stockholders voted on the following four proposals, each of which is described in detail in the definitive proxy statement filed with the Securities and Exchange Commission on April 20, 2021.
The final results for each of the matters considered at the Annual Meeting were as follows:
PROPOSAL I: Election of Directors
The director nominees were elected to serve as a Class III directors until the Company’s annual meeting of stockholders in 2024, or until their successor is duly elected and qualified, or their earlier resignation, death, or removal. Due to plurality election, votes could only be cast in favor of or withheld from the nominees and thus votes against were not applicable. The results of the election were as follows:

Lilian Shackelford Murray5,534,072319,7144,987,036
Amy Yoder5,534,072319,7144,987,036

PROPOSAL II: Ratification of Selection of Independent Registered Public Accountants
The appointment of Deloitte & Touche LLP as the Company’s independent registered public accountants for the year ending December 31, 2021, was ratified by the affirmative votes of the stockholders. There were no broker non-votes on this proposal. The results of the ratification were as follows:


PROPOSAL III: Advisory Vote on Executive Compensation
The Company’s shareholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers by the votes set forth in the table below:


PROPOSAL IV: Advisory Vote on the Frequency of the Advisory, Non-binding Vote on Executive Compensation
The Company’s shareholders voted to approve, on an advisory basis, a frequency of one year for the advisory vote on compensation paid to the Company’s named executive officers, by the votes set forth in the table below: